SCHEMBL5962898

SCHEMBL5962898

COc1ccc2c(c1OC)C(=O)N1CC(O[Si](C)(C)C(C)(C)C)C[C@H]1C(=O)N2

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.33
SMN1; SMN2 Q16637 4/20 0.33
KDM4E B2RXH2 4/20 0.33
HSD17B10 Q99714 3/20 0.33
HPGD P15428 2/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
MAPT P10636 5/20 0.32
HTT P42858 1/20 0.32
LMNA P02545 2/20 0.32
POLB P06746 2/20 0.32
VHL P40337 1/20 0.32
ELOC Q15369 1/20 0.32
ELOB Q15370 1/20 0.32
MEN1 O00255 1/20 0.32
GFER P55789 1/20 0.32
KMT2A Q03164 1/20 0.32
NPC1 O15118 2/20 0.31
TP53 P04637 2/20 0.31
RAB9A P51151 2/20 0.31
ALPL P05186 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1121820 1.00 ALDH1A1 (0.33) ALDH1A1SMN1; SMN2KDM4EHSD17B10HPGD
SCHEMBL14090164 0.81 HTR2A (0.33) ALDH1A1KDM4EVHLELOCELOB
SCHEMBL29778228 0.79 PDE3B (0.38) ALDH1A1SMN1; SMN2KDM4EHPGDL3MBTL1
SCHEMBL1121876 0.79 NPC1 (0.36) ALDH1A1SMN1; SMN2KDM4EHSD17B10HPGD
SCHEMBL1121875 0.79 NPC1 (0.36) ALDH1A1SMN1; SMN2KDM4EHSD17B10HPGD
SCHEMBL23837196 0.78 EGFR (0.35) VHLELOCELOBACHEHTR2C
SCHEMBL7981364 0.77 GFER (0.36) ALDH1A1KDM4EHSD17B10HPGDMAPT
SCHEMBL31436222 0.74 VHL (0.35) VHLELOCELOB
SCHEMBL17489316 0.74 POLB (0.36) KDM4EMAPTLMNAPOLBMEN1
SCHEMBL5962742 0.73

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7067511-B2 Pyrrolobenzodiazepines SPIROGEN LIMITED (GB) 2006-06-27 US disclosed
US-7049311-B1 Pyrrolbenzodiazepines SPIROGEN LIMITED (GB) 2006-05-23 US disclosed
EP-1109812-B1 PYRROLOBENZODIAZEPINES SPIROGEN LTD (GB) 2005-05-04 EP disclosed
EP-1413582-A1 Dimeric pyrrolobenzodiazepines Spirogen Limited (GB) 2004-04-28 EP disclosed
US-20030120069-A1 Pyrrolobenzodiazepines SPIROGEN LIMITED (GB) 2003-06-26 US disclosed
EP-1193270-A2 Pyrrolobenzodiazepines Spirogen Limited (GB) 2002-04-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030120069-A1 Pyrrolobenzodiazepines CNR1, CBX2, CNR2 ALDH1A1 4469/4885SMN1; SMN2 2936/4885KDM4E 2997/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.